Martín, Teresa
Guimarães, Catarina
Esquinas, Cristina
Torres-Duran, Maria
Turner, Alice M.
Tanash, Hanan
Rodríguez-García, Carlota
Corsico, Angelo
López-Campos, José Luis
Bartošovská, Eva
Stæhr Jensen, Jens-Ulrik
Hernández-Pérez, José María
Sucena, Maria
Miravitlles, Marc
Article History
Received: 20 February 2024
Accepted: 12 June 2024
First Online: 26 June 2024
Declarations
:
: The study protocol received central ethics approval by the research ethics committee of the Vall d’Hebron University Hospital of Barcelona, Spain (PR(AG)480/2018) and was subsequently approved by all participating centres. All participants provided written informed consent.
: Not applicable.
: Teresa Martín has received speaker fees from AstraZeneca, CSL Behring, and GlaxoSmithKline, consulting fees from GlaxoSmithKline, and support for attending meetings from AstraZeneca, Bial, Boehringer Ingelheim, CSL Behring, Novartis and Medinfar. Catarina Guimarães has received speaker fees from CSL Behring. Cristina Esquinas has received speaker fees from CSL Behring. María Torres-Durán has received either speaker and consulting fees from CSL Behring and Grifols, and support for attending meetings from CSL Behring, Grifols, Chiesi and FAES Farma. Alice M Turner has received either grants or speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, CSL Behring, Takeda, Vertex and Grifols Biotherapeutics. Hanan Tanash has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Chiesi and Grifols. Carlota Rodríguez-García has received speaker fees from AstraZeneca, GlaxoSmithKline, Grifols, Chiesi, and CSL Behring, expert testimony for Chiesi, support for attending meetings from Chiesi and Grifols. Angelo Corsico has received speaker fees and honoraria for participation on advisory board from CSL Behring, and honoraria for manuscript writing from Grifols. José Luis López-Campos has received honoraria during the last 3 years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Faes, Gebro Pharma, GlaxoSmithKline, Grifols, Megalabs and Menarini. José María Hernández-Pérez has received consulting fees from Grifols and CSL Behring, speaker fees from AstraZeneca, Bial, CSL Behring, FAES laboratory, GlaxoSmithKline, and Grifols, support for attending meetings from Grifols and CSL Behring, and honoraria for participation on advisory board from Grifols. Maria Sucena has received consulting fees from Bial, CSL Behring and Grifols, speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, CSL Behring, Grifols and Novartis, support for attending meetings from Bial, CSL Behring, DarSaúde, Gasoxmed, Grifols, Medinfar and VitalAire, honoraria for participation on advisory board from Bial and CSL Behring. Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Kamada, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, Spin Therapeutics, pH Pharma, Novartis, Sanofi and Grifols and research grants from Grifols. The remaining authors report no competing interests.